FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...

(Saint-lgnace-de-Stanbridge, Quebec) May 27th, 2023 – FORUS Therapeutics was a proud sponsor of the 11th Edition of the Défi Cyclo-Myélome. The Défi Cyclo-Myélome provides support to Dr. Richard LeBlanc, holder of the Université de Montréal Myeloma Canada Chair on...

(OAKVILLE, Ontario) le 24 mai 2023 – FORUS Therapeutics Inc (« FORUS ») et l'Alliance pancanadienne pharmaceutique (« APP ») ont achevé les négociations d'une lettre d'intention concernant XPOVIOMD (sélinexor) en association avec le bortézomib et la dexaméthasone pour...

(TORONTO, Ontario) April 25-26, 2023 ­– It was an honour to share the FORUS Therapeutics corporate update on April 25 at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto. We are very proud of the important commercialization milestones our team...

FORUS Therapeutics is delighted to welcome Vania Brennan as Therapeutic Area Manager, Hematology/Oncology, BC/AB.  Vania is well recognized as a therapeutic expert in the field of hematology and oncology with over 20 years experience in this space, in commercial and...

FORUS Therapeutics is delighted to welcome Nancy Davies as Therapeutic Area Manager, Hematology/Oncology, GTA W/Southwest ONT.  Nancy brings to this role her significant experience across various therapeutic areas, with a long history and passion for...

FORUS Therapeutics a le plaisir d’accueillir Michel St-Pierre en tant que gestionnaire du secteur thérapeutique, en hématologie et oncologie, au Québec.  Michel possède une vaste expérience des rôles commerciaux dans l’industrie des soins de santé, ainsi que dans le...

FORUS Therapeutics a le plaisir d’accueillir Annie Blyth en tant que gestionnaire du secteur thérapeutique, en hématologie et oncologie, dans l’Est de l’Ontario et au Manitoba.  Annie possède une vaste expérience et une grande expertise dans divers domaines...

FORUS Therapeutics is thrilled to welcome Jagroop Dhaliwal, to the department of Medical and Scientific Affairs as an Intern through the Pharmaceutical & Healthcare Management and Innovation graduate program at Queen’s University. Jagroop has a Ph.D. in...

FORUS Therapeutics is thrilled to announce Elaine Lai PharmD, is joining our team as Associate Product and Patient Support Manager. Elaine has already made significant contributions to the FORUS Mission and Vision over the past year, during her internship through the...

(TORONTO, Ontario) October 25, 2022 ­– A big thank you to the TSX/TSXV for hosting the Life Science Investor Day forum in downtown Toronto on Oct 25, 2022, and to the sponsors Life Sciences Ontario, MNP, NATIONAL, TORYS LLP. FORUS Therapeutics was proud to be a...